All articles tagged with #metformin
Scientists reveal metformin lowers blood sugar by acting in the brain, specifically by suppressing Rap1 in the ventromedial hypothalamus and activating SF1 neurons, with brain effects at far lower drug levels than previously thought, opening possibilities for brain-targeted diabetes therapies and potential brain-health benefits.
New research shows metformin can act in the brain, reaching the ventromedial hypothalamus and inhibiting Rap1 signaling in SF1 neurons to help regulate glucose in mice, a mechanism distinct from its liver and gut effects. When Rap1 was removed, metformin no longer helped diabetes-like symptoms, suggesting a brain pathway. This could lead to brain-targeted diabetes therapies and broaden metformin’s uses, though human studies are needed and side effects like GI distress and kidney risk remain concerns; the drug is also linked to aging benefits.
New preclinical work links metformin’s metabolic effects to the brain, showing it acts in the hypothalamus via the Rap1 pathway to enhance central insulin signaling and reduce liver glucose production in mice. This brain-first mechanism could reshape diabetes and obesity therapies, informing drug combinations and trial endpoints, but human validation is needed and questions remain about dosing, blood–brain barrier crossing, and interactions with AMPK.
A 26-week randomized trial (INTIMET) in 40 adults with long-standing type 1 diabetes found metformin did not improve insulin resistance or glucose control, but reduced total daily insulin requirements by about 12% compared with placebo, suggesting metformin may ease the insulin burden rather than reverse insulin resistance; researchers are exploring whether gut microbiome interactions explain the effect.
A study of 438 postmenopausal women with type 2 diabetes suggests that starting metformin is associated with about a 30% lower risk of dying before age 90 compared with sulfonylurea therapy, hinting at metformin's potential aging‑related benefits. However, the findings are observational (not randomized), with no placebo group and a modest sample size; the long follow‑up of 14–15 years strengthens the signal but cannot prove causality, and randomized trials are needed to confirm longevity effects.
A Liverpool study of about 2,000 adults with diabetes aged 50+ found that those taking metformin had 37% lower odds of developing intermediate age-related macular degeneration (AMD) over five years compared with non-users, suggesting metformin might help slow age-related vision loss. However, researchers caution that the findings are observational and do not prove causation or support using metformin to treat AMD outside of diabetes; clinical trials are needed to confirm any benefit.
A literature review of randomized trials and health-record analyses suggests that taking metformin during acute COVID-19 can reduce the risk of developing long COVID by roughly 40%–60%, though it is studied for prevention rather than treatment of existing long COVID; findings, including the COVID-OUT trial and EHR-based studies, have replicated this protective effect and point to possible antiviral benefits and compatibility with other antivirals, making metformin a potential low-cost outpatient preventive option.
Recent research suggests that diabetes drugs like metformin, SGLT2 inhibitors, and GLP-1 receptor agonists may influence cancer risk and progression through mechanisms beyond blood sugar control, affecting inflammation, immune responses, and cellular signaling, highlighting potential therapeutic opportunities and the need for further studies.
Scientists have discovered that metformin, a widely used diabetes drug, works through a brain pathway involving the ventromedial hypothalamus and a protein called Rap1, revealing new insights into its mechanism and potential effects on appetite, weight, and cognition. More research is needed, but these findings could lead to improved treatments for diabetes and other neurological conditions.
Scientists have discovered that the diabetes drug metformin impacts the brain, particularly through a pathway involving the ventromedial hypothalamus and a protein called Rap1, which may explain some of its effects on weight, appetite, and cognition. This new understanding could lead to broader applications of the drug beyond blood sugar control, although further research is needed, especially in humans.
A 16-week study from Rutgers University found that metformin, a common diabetes drug, may reduce the health benefits of exercise, including improvements in blood vessel function, fitness, and blood sugar control, raising questions about combined treatment strategies for metabolic syndrome and diabetes prevention.
A Rutgers study warns that the diabetes drug metformin may reduce the health benefits of exercise, including improvements in blood vessel function, fitness, and blood sugar regulation, raising concerns about combined treatment strategies for at-risk individuals.
A Rutgers-led study found that metformin may reduce the benefits of exercise on blood vessel function, fitness, and blood sugar control, raising concerns about its combined use for diabetes prevention and treatment. The research suggests that metformin could interfere with cellular adaptations to exercise, potentially impacting long-term health outcomes for at-risk individuals.
Long-term use of medications like metformin and proton pump inhibitors can impair vitamin B12 absorption, leading to deficiency symptoms such as fatigue, numbness, and cognitive changes. Regular B12 testing is recommended for those on these drugs to detect and treat deficiencies early.
Early clinical trial results suggest that combining a common diabetes drug with an antihistamine may partially repair nerve damage in multiple sclerosis, offering hope for a new class of therapies, although the effects observed were small and not yet clinically noticeable.